Skip to main content

Table 2 Univariate analysis of possible prognostic factors and impact of first-line treatment modalities on PFS and OS

From: Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement

 

PFS

OS

HR [95% CI]

P

HR [95% CI]

P

Age >60 years

2.85 [1.19, 6.86]

0.02

3.70 [1.22, 11.22]

0.02

Ann Arbor stage IIIE-IVE

4.92 [1.67, 14.52]

0.004

6.41 [1.43, 28.59]

0.01

LDH above normal

2.18 [0.89, 5.33]

0.09

2.29 [0.72, 7.26]

0.16

ECOG >1

3.34 [1.45, 7.70]

0.005

4.27 [1.54, 11.83]

0.005

No. of extranodal sites

  > 1

  > 2

  > 3

1.24 [0.50, 3.05]

2.64 [1.09, 6.36]

5.69 [1.99, 16.31]

0.64

0.03

0.001

1.11 [0.38, 3.27]

2.56 [0.87, 7.51]

5.91 [1.79, 19.53]

0.85

0.09

0.004

hypercalcemia

4.69 [1.57, 14.03]

0.006

7.52 [2.34, 24.12]

0.0007

AP above normal

0.88 [0.35, 2.16]

0.77

0.71 [0.22, 2.24]

0.56

Multifocal bone lesions

1.10 [0.48, 2.52]

0.83

1.23 [0.44, 3.46]

0.69

Rituximab

0.76 [0.29, 2.00]

0.58

1.12 [0.30, 4.14]

0.87

Intensified chemotherapy

0.44 [0.16, 1.18]

0.10

0.44 [0.12, 1.57]

0.21

Radiotherapy

0.55 [0.20, 1.47]

0.23

0.09 [0.01, 0.72]

0.02

  1. Abbreviations: HR indicates hazard ratio, CI confidence interval, and P p-value